Giovanni Nassa
Overview
Explore the profile of Giovanni Nassa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alexandrova E, Smal M, Di Rosa D, Brancaccio R, Parisi R, Russo F, et al.
Sci Rep
. 2025 Mar;
15(1):7602.
PMID: 40038391
Ovarian Cancer (OC) is the most lethal gynecological malignancy, characterized by peritoneal metastasis, directly linked to most OC-related deaths. Here, by interrogating CRISPR-Cas9 loss-of-function genetic screen data, we identified a...
2.
Montico B, Giurato G, Guerrieri R, Colizzi F, Salvati A, Nassa G, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):53.
PMID: 39953610
Background: About 50% of cutaneous melanoma (CM) harbors the activating BRAF mutation which exerts most of the oncogenic effects through the MAPK signaling pathway. In the last years, a number...
3.
Melone V, Palumbo D, Palo L, Brusco N, Salvati A, Tarallo A, et al.
Cell Death Dis
. 2025 Feb;
16(1):80.
PMID: 39922814
RNA-based therapeutics highlighted novel approaches to target either coding or noncoding molecules for multiple diseases treatment. In breast cancer (BC), a multitude of deregulated long noncoding RNAs (lncRNAs) have been...
4.
Salvati A, Giurato G, Lamberti J, Terenzi I, Crescenzo L, Melone V, et al.
Mol Cancer
. 2024 Aug;
23(1):160.
PMID: 39113071
Identifying master epigenetic factors controlling proliferation and survival of cancer cells allows to discover new molecular targets exploitable to overcome resistance to current pharmacological regimens. In breast cancer (BC), resistance...
5.
Smal M, Memoli D, Alexandrova E, Di Rosa D, DAgostino Y, Russo F, et al.
Sci Data
. 2024 Jul;
11(1):767.
PMID: 38997254
Small non-coding RNAs (sncRNAs) make up ~1% of the transcriptome; nevertheless, they play significant roles in regulating cellular processes. Given the complexity of the central nervous system, sncRNAs likely hold...
6.
Polcaro G, Liguori L, Manzo V, Chianese A, Donadio G, Caputo A, et al.
Mol Cancer
. 2024 Mar;
23(1):63.
PMID: 38528526
Efficient predictive biomarkers are needed for immune checkpoint inhibitor (ICI)-based immunotherapy in non-small cell lung cancer (NSCLC). Testing the predictive value of single nucleotide polymorphisms (SNPs) in programmed cell death...
7.
Whole Genome Sequence Dataset of Mycobacterium tuberculosis Strains from Patients of Campania Region
Folliero V, Ferravante C, Iovane V, Salvati A, Crescenzo L, Perna R, et al.
Sci Data
. 2024 Feb;
11(1):220.
PMID: 38374088
Tuberculosis (TB) is one of the deadliest infectious disorders in the world. To effectively TB manage, an essential step is to gain insight into the lineage of Mycobacterium tuberculosis (MTB)...
8.
Giurato G, Terenzi I, Chiuso F, Salvati A, Rizzo F, Tarallo R, et al.
Front Cell Dev Biol
. 2023 Dec;
11:1308025.
PMID: 38099289
No abstract available.
9.
Saggese P, Pandey A, Alcaraz Jr M, Fung E, Hall A, Yanagawa J, et al.
Cancer Res
. 2023 Nov;
84(2):305-327.
PMID: 37934116
Significance: Epigenetic adaptation allows cancer cells to overcome the tumor-suppressive effects of glucose restriction by inducing dedifferentiation and an aggressive phenotype, which could help design better metabolic treatments.
10.
Di Donato M, Di Zazzo E, Salvati A, Sorrentino C, Giurato G, Fiore D, et al.
J Transl Med
. 2023 Oct;
21(1):736.
PMID: 37853459
Background: Colorectal cancer (CRC) is the third most deadly and fourth most diagnosed cancer worldwide. Despite the progress in early diagnosis and advanced therapeutic options, CRC shows a poor prognosis...